Cyclotron technology developer Ionetix has produced the first batch of therapeutic radioisotope astatine-211 (At-211) at its new alpha isotope manufacturing facility in Lansing, MI.
The company said it completed the installation of the first of two cyclotrons at the facility earlier this year and that initial commissioning was successfully completed in March. The cyclotron is a multiparticle, 30 MeV cyclotron. Once fully optimized, it will be used to generate high yields of At-211 as well as actinium-225 (Ac-225), a radioitotope used in imaging, according to Ionetix.
The firm said it expects the facility to be fully operational in the fourth quarter of 2023 and plans to submit a Drug Master File for Ac-225 to the U.S. Food and Drug Administration (FDA) in early 2024.
